BACKGROUND: Antiretroviral therapy (ART) in resource-limited settings (RLSs) is monitored clinically and immunologically, according to World Health Organization (WHO) or national guidelines. Revised WHO pediatric guidelines were published in 2010, but their ability to accurately identify virological failure is unclear. METHODS: We evaluated performance of WHO 2010 guidelines and compared them with WHO 2006 and Cambodia 2011 guidelines among children on ≥6 months of first-line ART at Angkor Hospital for Children between January 2005 and September 2010. We determined sensitivity, specificity, positive and negative predictive values, and accuracy using bootstrap resampling to account for multiple tests per child. Human immunodeficiency virus (HIV) resistance was compared between those correctly and incorrectly identified by each guideline. RESULTS: Among 457 children with 1079 viral loads (VLs), 20% had >400 copies/mL. For children with WHO stage 1/2 HIV, misclassification as failure (met CD4 failure criteria, but VL undetectable) was 64% for WHO 2006 guidelines, 33% for WHO 2010 guidelines, and 81% for Cambodia 2011 guidelines; misclassification as success (did not meet CD4 failure, but VL detectable) was 11%, 12%, and 12%, respectively. For children with WHO stage 3/4 HIV, misclassification as failure was 35% for WHO 2006 guidelines, 40% for WHO 2010 guidelines, and 43% for Cambodia 2011 guidelines; misclassification as success was 13%, 24%, and 21%, respectively. Compared with WHO 2006 guidelines, WHO 2010 guidelines significantly increased the risk of misclassification as success in stage 3/4 HIV (P < .05). The WHO 2010 guidelines failed to identify 98% of children with extensive reverse-transcriptase resistance. CONCLUSIONS: In our cohort, lack of virological monitoring would result in unacceptable treatment failure misclassification, leading to premature ART switch and resistance accumulation. Affordable virological monitoring suitable for use in RLSs is desperately needed.
BACKGROUND: Antiretroviral therapy (ART) in resource-limited settings (RLSs) is monitored clinically and immunologically, according to World Health Organization (WHO) or national guidelines. Revised WHO pediatric guidelines were published in 2010, but their ability to accurately identify virological failure is unclear. METHODS: We evaluated performance of WHO 2010 guidelines and compared them with WHO 2006 and Cambodia 2011 guidelines among children on ≥6 months of first-line ART at Angkor Hospital for Children between January 2005 and September 2010. We determined sensitivity, specificity, positive and negative predictive values, and accuracy using bootstrap resampling to account for multiple tests per child. Human immunodeficiency virus (HIV) resistance was compared between those correctly and incorrectly identified by each guideline. RESULTS: Among 457 children with 1079 viral loads (VLs), 20% had >400 copies/mL. For children with WHO stage 1/2 HIV, misclassification as failure (met CD4 failure criteria, but VL undetectable) was 64% for WHO 2006 guidelines, 33% for WHO 2010 guidelines, and 81% for Cambodia 2011 guidelines; misclassification as success (did not meet CD4 failure, but VL detectable) was 11%, 12%, and 12%, respectively. For children with WHO stage 3/4 HIV, misclassification as failure was 35% for WHO 2006 guidelines, 40% for WHO 2010 guidelines, and 43% for Cambodia 2011 guidelines; misclassification as success was 13%, 24%, and 21%, respectively. Compared with WHO 2006 guidelines, WHO 2010 guidelines significantly increased the risk of misclassification as success in stage 3/4 HIV (P < .05). The WHO 2010 guidelines failed to identify 98% of children with extensive reverse-transcriptase resistance. CONCLUSIONS: In our cohort, lack of virological monitoring would result in unacceptable treatment failure misclassification, leading to premature ART switch and resistance accumulation. Affordable virological monitoring suitable for use in RLSs is desperately needed.
Authors: Tulio de Oliveira; Koen Deforche; Sharon Cassol; Mika Salminen; Dimitris Paraskevis; Chris Seebregts; Joe Snoeck; Estrelita Janse van Rensburg; Annemarie M J Wensing; David A van de Vijver; Charles A Boucher; Ricardo Camacho; Anne-Mieke Vandamme Journal: Bioinformatics Date: 2005-08-02 Impact factor: 6.937
Authors: Allison K Delong; Mingham Wu; Diane Bennett; Neil Parkin; Zhijin Wu; Joseph W Hogan; Rami Kantor Journal: AIDS Res Hum Retroviruses Date: 2011-10-26 Impact factor: 2.205
Authors: Susan D Emmett; Coleen K Cunningham; Blandina T Mmbaga; Grace D Kinabo; Werner Schimana; Mark E Swai; John A Bartlett; John A Crump; Elizabeth A Reddy Journal: J Acquir Immune Defic Syndr Date: 2010-08 Impact factor: 3.731
Authors: Kim C E Sigaloff; Raph L Hamers; Carole L Wallis; Cissy Kityo; Margaret Siwale; Prudence Ive; Mariette E Botes; Kishor Mandaliya; Maureen Wellington; Akin Osibogun; Wendy S Stevens; Michèle van Vugt; Tobias F Rinke de Wit Journal: J Acquir Immune Defic Syndr Date: 2011-09-01 Impact factor: 3.731
Authors: Mia Coetzer; Benjamin Westley; Allison Delong; Chhraing Tray; Dim Sophearin; Eric Nerrienet; Leeann Schreier; Rami Kantor Journal: AIDS Res Hum Retroviruses Date: 2013-04-27 Impact factor: 2.205
Authors: Paola Costenaro; Rebecca Lundin; Maria Raffaella Petrara; Martina Penazzato; William Massavon; Susan Kizito; Sandra Monica Nabachwa; Maria Nannyonga Musoke; Charles Namisi; Erika Morelli; Davide Bilardi; Antonio Mazza; Marisa Zanchetta; Carlo Giaquinto; Anita De Rossi Journal: J Clin Microbiol Date: 2014-04-30 Impact factor: 5.948
Authors: Maya L Petersen; Erin LeDell; Joshua Schwab; Varada Sarovar; Robert Gross; Nancy Reynolds; Jessica E Haberer; Kathy Goggin; Carol Golin; Julia Arnsten; Marc I Rosen; Robert H Remien; David Etoori; Ira B Wilson; Jane M Simoni; Judith A Erlen; Mark J van der Laan; Honghu Liu; David R Bangsberg Journal: J Acquir Immune Defic Syndr Date: 2015-05-01 Impact factor: 3.731
Authors: Elizabeth M Dufort; Allison K DeLong; Marita Mann; Winstone M Nyandiko; Samuel O Ayaya; Joseph W Hogan; Rami Kantor Journal: J Pediatric Infect Dis Soc Date: 2017-09-01 Impact factor: 3.164
Authors: Carina Cesar; Cathy A Jenkins; Bryan E Shepherd; Denis Padgett; Fernando Mejía; Sayonara Rocha Ribeiro; Claudia P Cortes; Jean W Pape; Juan Sierra Madero; Valeria Fink; Omar Sued; Catherine McGowan; Pedro Cahn Journal: Lancet HIV Date: 2015-10-22 Impact factor: 12.767
Authors: Maya L Petersen; Linh Tran; Elvin H Geng; Steven J Reynolds; Andrew Kambugu; Robin Wood; David R Bangsberg; Constantin T Yiannoutsos; Steven G Deeks; Jeffrey N Martin Journal: AIDS Date: 2014-09-10 Impact factor: 4.177